Testing effectiveness (Phase 2)Study completedNCT01813734What this trial is testingPonatinib in Advanced NSCLC w/ RET TranslocationsWho this might be right forNon Small Cell Lung Cancer Massachusetts General Hospital 9
Testing effectiveness (Phase 2)Study completedNCT01831726What this trial is testingDovitinib for Patients With Tumor Pathway Activations Inhibited by DovitinibWho this might be right forTumor Pathway Activations Inhibited by Dovitinib Novartis Pharmaceuticals 80
Not applicableUnknownNCT04921553What this trial is testingReal Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)Who this might be right forCancerCancer MetastaticNTRK Gene Fusion Overexpression+13 more Centre Leon Berard 500
Testing effectiveness (Phase 2)Active Not RecruitingNCT03157128What this trial is testingSelpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)Who this might be right forNon-Small Cell Lung CancerMedullary Thyroid CancerColon Cancer+1 more Eli Lilly and Company 857
Testing effectiveness (Phase 2)Active Not RecruitingNCT03899792What this trial is testingOral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) TumorsWho this might be right forMedullary Thyroid CancerInfantile MyofibromatosisInfantile Fibrosarcoma+2 more Eli Lilly and Company 36